A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.

Abstract:

:Chromosomal breakpoints associated with malignancy are known to cluster at particular regions of the karyotype. Based on a review of the literature we have identified a novel leukaemia syndrome associated with translocations involving 8p11. This syndrome is distinct from the previously described translocation t(8;16)(p11;p13) associated with acute monoblastic leukaemia. We have summarized the clinical and cytogenetic features of 13 case reports which describe a myeloproliferative syndrome with eosinophilia, lymphadenopathy and a high incidence of T cell non-Hodgkin's lymphoma with progression to acute myeloid leukaemia. The translocations involving 8p11 were: either t(8;13)(p11-12;q11-12), t(8;9) (p11;q32-34) or t(6;8)(q27;p12). In two cases of t(8;13) molecular studies have mapped the chromosome 13 breakpoint to a 1.5 Mbp region, but a full molecular characterization of these translocations is required. In view of the striking clinicopathological and karyotypic similarities between these cases we propose that they be considered a single nosological entity and termed '8p11 myeloproliferative syndrome'.

journal_name

Leukemia

journal_title

Leukemia

authors

Macdonald D,Aguiar RC,Mason PJ,Goldman JM,Cross NC

subject

Has Abstract

pub_date

1995-10-01 00:00:00

pages

1628-30

issue

10

eissn

0887-6924

issn

1476-5551

journal_volume

9

pub_type

杂志文章,评审

相关文献

LEUKEMIA文献大全
  • Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.

    abstract::Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Griffiths SD,Cawley JC

    更新日期:1988-06-01 00:00:00

  • Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

    abstract::Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by ex...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.24

    authors: Hoellenriegel J,Coffey GP,Sinha U,Pandey A,Sivina M,Ferrajoli A,Ravandi F,Wierda WG,O'Brien S,Keating MJ,Burger JA

    更新日期:2012-07-01 00:00:00

  • Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

    abstract::Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate ant...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.50

    authors: Wild J,Schmiedel BJ,Maurer A,Raab S,Prokop L,Stevanović S,Dörfel D,Schneider P,Salih HR

    更新日期:2015-08-01 00:00:00

  • Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.

    abstract::The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404057

    authors: Nyåkern M,Tazzari PL,Finelli C,Bosi C,Follo MY,Grafone T,Piccaluga PP,Martinelli G,Cocco L,Martelli AM

    更新日期:2006-02-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.260

    authors: Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期:2017-03-01 00:00:00

  • Clinical significance of chromosome abnormalities in childhood acute lymphoblastic leukemia in Japan.

    abstract::Of 240 Japanese children with acute lymphoblastic leukemia (ALL) treated between 1983 and 1990, 75 (31%) had normal diploidy, 47 (20%) hyperdiploidy with more than 50 chromosomes, 18 (8%) hyperdiploidy with 47-50 chromosomes, 77 (32%) pseudodiploidy, 22 (9%) hypodiploidy and one hypotetraploidy in the leukemic cells. ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kobayashi H,Maseki N,Homma C,Sakurai M,Kaneko Y

    更新日期:1994-11-01 00:00:00

  • Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.

    abstract::In B-CLL IgV(H) genes mutational status is a major prognostic factor. Since sequencing of IgV(H) genes is not available in most laboratories, an easily performed surrogate assay is desirable. To identify the best surrogate assay, and to better discriminate prognostic subgroups we analyzed clinical and biological data ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402780

    authors: Magnac C,Porcher R,Davi F,Nataf J,Payelle-Brogard B,Tang RP,Oppezzo P,Lévy V,Dighiero G,Ajchenbaum-Cymbalista F

    更新日期:2003-01-01 00:00:00

  • Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.

    abstract::Sorafenib, a novel drug for metastatic renal cancer, has broad-spectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and platelet-derived growth factor receptor. However, little is known about its effects on the immune system. In this report, we examine the e...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.58

    authors: Zhao W,Gu YH,Song R,Qu BQ,Xu Q

    更新日期:2008-06-01 00:00:00

  • Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody.

    abstract::The alpha chain of the interleukin 2 receptor (IL2R alpha; Tac) was targeted in clinical trials with adult T cell leukemia using murine anti-Tac antibody. Of 19 patients, a single individual achieved a durable complete remission. The mechanism of this action by murine anti-Tac has not been defined. We examined the hyp...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401048

    authors: Kingsbury GA,Waldmann TA,Junghans RP

    更新日期:1998-06-01 00:00:00

  • Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) - a report of the Children's Cancer Group.

    abstract::Infants less than 1 year of age at diagnosis of acute lymphoblastic leukemia (ALL) have a poor prognosis, which has been attributed primarily to a breakpoint in chromosomal band 11q23 or the MLL gene. Most infants with an 11q23 breakpoint have a t(4;11)(q21 ;q23). We studied the cytogenetics of the leukemia cells of 5...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401413

    authors: Heerema NA,Sather HN,Ge J,Arthur DC,Hilden JM,Trigg ME,Reaman GH

    更新日期:1999-05-01 00:00:00

  • Treatment and unmet needs in steroid-refractory acute graft-versus-host disease.

    abstract::Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and mortality. Systemic steroid therapy is the first-line treatment for aGVHD, although about half of patients will become refractory to treatment. As the n...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0804-2

    authors: Malard F,Huang XJ,Sim JPY

    更新日期:2020-05-01 00:00:00

  • High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) is a moderately aggressive B-cell lymphoma that responds poorly to currently used therapeutic protocols. In order to identify tumour characteristics that improve the understanding of biology of MCL, analysis of oligonucleotide microarrays were used to define specific gene expression profiles...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403057

    authors: Islam TC,Asplund AC,Lindvall JM,Nygren L,Liden J,Kimby E,Christensson B,Smith CI,Sander B

    更新日期:2003-09-01 00:00:00

  • Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

    abstract::The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytomet...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.42

    authors: Paiva B,Gutiérrez NC,Chen X,Vídriales MB,Montalbán MÁ,Rosiñol L,Oriol A,Martínez-López J,Mateos MV,López-Corral L,Díaz-Rodríguez E,Pérez JJ,Fernández-Redondo E,de Arriba F,Palomera L,Bengoechea E,Terol MJ,de Paz R,Mar

    更新日期:2012-08-01 00:00:00

  • TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.

    abstract::T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0864-3

    authors: Bamezai S,Demir D,Pulikkottil AJ,Ciccarone F,Fischbein E,Sinha A,Borga C,Te Kronnie G,Meyer LH,Mohr F,Götze M,Caiafa P,Debatin KM,Döhner K,Döhner H,González-Menéndez I,Quintanilla-Fend L,Herold T,Jeremias I,Feuring-

    更新日期:2020-05-15 00:00:00

  • Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.

    abstract::Chronic graft-versus-host disease (GVHD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HCT). In 2005 the National Institutes of Health (NIH) established new criteria for chronic GVHD based on retrospective data and expert recommendations. We prospectively evaluated the incide...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.257

    authors: Kuzmina Z,Eder S,Böhm A,Pernicka E,Vormittag L,Kalhs P,Petkov V,Stary G,Nepp J,Knobler R,Just U,Krenn K,Worel N,Greinix HT

    更新日期:2012-04-01 00:00:00

  • Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.

    abstract::The NUP214-ABL1 fusion kinase has recently been identified in 6% of patients with T-cell acute lymphoblastic leukemia. In contrast to the more common oncogenic ABL1 fusion BCR-ABL1, NUP214-ABL1 localizes to the nuclear pore complexes and has attenuated transforming properties in hematopoietic cells and in mouse bone m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.242

    authors: De Keersmaecker K,Versele M,Cools J,Superti-Furga G,Hantschel O

    更新日期:2008-12-01 00:00:00

  • Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

    abstract::Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.194

    authors: Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

    更新日期:2013-12-01 00:00:00

  • Effects of clinical combinations of antileukemic drugs on DNA ligase from human thymocytes and normal, stimulated, or leukemic lymphocytes.

    abstract::Human DNA ligase was purified from different kinds of immunocompetent cells: thymocytes, normal and stimulated lymphocytes, blasts from ALL (Burkitt and non-T, non-B) and ANLL (M1, M2, and M5). Based upon the protocol for the treatment of these leukemias, the purified enzymes were assayed in the presence of routinely ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lamballe F,Maniey D,Boscher MY,Fauchet R,le Prise PY,David JC

    更新日期:1988-06-01 00:00:00

  • Relation between cell cycle stage and the activity of DNA-synthesizing enzymes in cultured human lymphoblasts: investigations on cells separated according to DNA content by way of a cell sorter.

    abstract::Exponentially growing human lymphoblasts (culture LS-2) were separated by cell sorting (FACS II, Becton Dickinson) according to their deoxyribonucleic acid (DNA) content, designating them at particular phases of the cell cycle. Prior to cell sorting the DNA has been fluorochrome-labeled with the Hoechst stain H 33342....

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pelka-Fleischer R,Fleischer W,Wilmanns W,Sauer H,Schalhorn A

    更新日期:1989-05-01 00:00:00

  • Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL.

    abstract::Although reciprocal chromosomal translocations are not typical for B-cell chronic lymphocytic leukemia (B-CLL), we identified the novel t(1;6)(p35.3;p25.2) in eight patients with this disorder. Interestingly, all cases showed lack of somatically mutated IgV(H). Clinical, morphological, immunologic, and genetic feature...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403543

    authors: Michaux L,Wlodarska I,Rack K,Stul M,Criel A,Maerevoet M,Marichal S,Demuynck H,Mineur P,Kargar Samani K,Van Hoof A,Ferrant A,Marynen P,Hagemeijer A

    更新日期:2005-01-01 00:00:00

  • The vascular niche: home for normal and malignant hematopoietic stem cells.

    abstract::Hematopoietic stem cells (HSCs) are uniquely capable of self-renewal and provision of all of the mature elements of the blood and immune system throughout the lifetime of an individual. HSC self-renewal is regulated by both intrinsic mechanisms and extrinsic signals mediated via specialized microenvironments or 'niche...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2011.236

    authors: Doan PL,Chute JP

    更新日期:2012-01-01 00:00:00

  • Quality assurance in RT-PCR-based BCR/ABL diagnostics--results of an interlaboratory test and a standardization approach.

    abstract::Here we describe the results of an interlaboratory test for RT-PCR-based BCR/ABL analysis. The test was organized in two parts. The number of participating laboratories in the first and second part was 27 and 20, respectively. In the first part samples containing various concentrations of plasmids with the ela2, b2a2 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401899

    authors: Burmeister T,Maurer J,Aivado M,Elmaagacli AH,Grünebach F,Held KR,Hess G,Hochhaus A,Höppner W,Lentes KU,Lübbert M,Schäfer KL,Schafhausen P,Schmidt CA,Schüler F,Seeger K,Seelig R,Thiede C,Viehmann S,Weber C,Wilhelm

    更新日期:2000-10-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract::Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.283

    authors: Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期:2011-03-01 00:00:00

  • Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII.

    abstract::To determine the frequency and prognostic significance of recently described genetic lesions in pediatric acute lymphoblastic leukemia (ALL), all cases with available leukemic cell samples treated on St Jude Study XII were analyzed by molecular techniques for alterations of the p16, MLL and ETV6 genes. Homozygous p16 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400779

    authors: Rubnitz JE,Behm FG,Pui CH,Evans WE,Relling MV,Raimondi SC,Harrison PL,Sandlund JT,Ribeiro RC,Grosveld G,Downing JR

    更新日期:1997-08-01 00:00:00

  • Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.

    abstract::We have developed a method to quantify topoisomerase (topo) II activities in partially purified nuclear extracts from human leukemia cells. By virtue of their different pH optima in the reaction buffer, two different topo II activities were found with activity optima at pH 7.9 and at pH 8.9 under high stringency condi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gieseler F,Glasmacher A,Kämpfe D,Wandt H,Nuessler V,Valsamas S,Kunze J,Wilms K

    更新日期:1996-07-01 00:00:00

  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

    abstract::Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/s41375-020-0718-z

    authors: Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CC

    更新日期:2020-07-01 00:00:00

  • Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

    abstract::The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug. However, most patients relapse after withdrawal of imatinib and advanced stage patients often develop drug resistance. As CML is considered a ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404638

    authors: Brendel C,Scharenberg C,Dohse M,Robey RW,Bates SE,Shukla S,Ambudkar SV,Wang Y,Wennemuth G,Burchert A,Boudriot U,Neubauer A

    更新日期:2007-06-01 00:00:00

  • bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis.

    abstract::We looked for bcl-2 protein expression by immunocytochemistry on bone marrow slides from 51 cases of myelodysplastic syndrome (MDS), of whom 25 received some form of chemotherapy. Forty-six of them had at least 20% bcl-2 positive blasts and the median percentage of positive blasts was 80%, whereas myeloid cells beyond...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lepelley P,Soenen V,Preudhomme C,Merlat A,Cosson A,Fenaux P

    更新日期:1995-04-01 00:00:00

  • CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

    abstract::FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer pot...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0009-0

    authors: Jetani H,Garcia-Cadenas I,Nerreter T,Thomas S,Rydzek J,Meijide JB,Bonig H,Herr W,Sierra J,Einsele H,Hudecek M

    更新日期:2018-05-01 00:00:00

  • Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A.

    abstract::The expansion of the Philadelphia (Ph) chromosome positive clone in chronic myeloid leukemia (CML) may depend on its capacity to suppress the proliferation of Ph-negative stem cells, but this proliferative advantage might, in certain circumstances, be reversible. Various lines of evidence suggest that Ph-negative cell...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Carella AM,Gaozza E,Raffo MR,Carlier P,Frassoni F,Valbonesi M,Lercari G,Sessarego M,Defferrari R,Guerrasio A

    更新日期:1991-06-01 00:00:00